INS and metabolic dysfunction-associated steatotic liver disease: Physicians need to be aware of surveillance and early intervention in NAFLD (weight loss, cardiovascular protection, insulin sensitization and lipid reduction) as the strategy to improve cardiovascular and liver outcomes.